Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H1 2018

  • ID: 4491169
  • Report
  • 57 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Bayer AG
  • Bristol-Myers Squibb Co
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • MORE
Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Pipeline Review, H1 2018

Summary:

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 17 molecules. Out of which approximately 16 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 4 and 8 respectively.

Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease which include indications Bleeding And Clotting Disorders, Thrombosis, Hemophilia C (Factor XI Deficiency), Sepsis, Venous Thromboembolism, Acute Ischemic Stroke, Arterial Thrombosis, Hemorrhagic Fever, Ischemic Stroke, Stroke and Venous (Vein) Thrombosis.

The latest report Coagulation Factor XI - Pipeline Review, H1 2018, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
  • The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer AG
  • Bristol-Myers Squibb Co
  • Ionis Pharmaceuticals Inc
  • Novartis AG
  • MORE
Introduction

Report Coverage

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Overview

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Companies Involved in Therapeutics Development

Bayer AG

Bio Products Laboratory Ltd

Bristol-Myers Squibb Co

Ionis Pharmaceuticals Inc

Mochida Pharmaceutical Co Ltd

Novartis AG

Sumitomo Dainippon Pharma Co Ltd

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Drug Profiles

AB-012 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AB-022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAY-1213790 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-262084 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-654457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-962212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

coagulation factor XI (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSR-130787 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EP-7041 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXILRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-FXIRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAA-868 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MR-1007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Factor XI for Bleeding And Clotting Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Dormant Products

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) - Product Development Milestones

Featured News & Press Releases

Nov 13, 2017: eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association

Jul 03, 2017: Bayer To Present Data on BAY 1213790 at ISTH 2

Nov 01, 2016: Ionis Pharmaceuticals Reports Positive Phase 2 Data for IONIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis

Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis

Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-

Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

Nov 18, 2014: Isis Pharmaceuticals to Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting

May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery

May 22, 2014: Cambryn Biologics Receives From FDA Orphan Drug Designation For Human Factor XI

Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma

Oct 29, 2012: Isis Pharma Initiates Phase II Study of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery

Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding

Feb 02, 2011: Isis Initiates Phase I Clinical Trial of ISIS-FXIRx To Treat Clotting Disorders

Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Indication, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products under Investigation by Universities/Institutes, H1 2018

Products under Investigation by Universities/Institutes, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Pipeline by Bayer AG, H1 2018

Pipeline by Bio Products Laboratory Ltd, H1 2018

Pipeline by Bristol-Myers Squibb Co, H1 2018

Pipeline by Ionis Pharmaceuticals Inc, H1 2018

Pipeline by Mochida Pharmaceutical Co Ltd, H1 2018

Pipeline by Novartis AG, H1 2018

Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2018

Dormant Projects, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Bayer AG
  • Bio Products Laboratory Ltd
  • Bristol-Myers Squibb Co
  • Ionis Pharmaceuticals Inc
  • Mochida Pharmaceutical Co Ltd
  • Novartis AG
  • Sumitomo Dainippon Pharma Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll